Insulet Stock Price, News & Analysis (NASDAQ:PODD)

Insulet trades on the NASDAQ under the ticker symbol "PODD."

Insulet Co. (NASDAQ:PODD) announced its quarterly earnings results on Monday, August, 5th. The medical instruments supplier reported $0.02 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.03 by $0.01. The medical instruments supplier earned $177.10 million during the quarter, compared to analyst estimates of $163.63 million. Insulet had a net margin of 2.66% and a return on equity of 7.85%. The company's revenue was up 42.5% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.03) earnings per share. View Insulet's Earnings History.

Insulet is scheduled to release their next quarterly earnings announcement on Tuesday, November 5th 2019. View Earnings Estimates for Insulet.

Insulet will be holding an earnings conference call on Tuesday, November 5th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Insulet issued an update on its third quarter 2019 earnings guidance on Monday, August, 5th. The company provided EPS guidance of for the period. The company issued revenue guidance of $174-181 million, compared to the consensus revenue estimate of $172.7 million.

14 brokerages have issued 1-year price targets for Insulet's shares. Their predictions range from $100.00 to $185.00. On average, they expect Insulet's stock price to reach $144.64 in the next year. This suggests that the stock has a possible downside of 7.9%. View Analyst Price Targets for Insulet.

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Insulet in the last year. There are currently 6 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Insulet.

News coverage about PODD stock has trended very negative this week, InfoTrie Sentiment Analysis reports. The research firm identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Insulet earned a media sentiment score of -3.2 on InfoTrie's scale. They also gave news articles about the medical instruments supplier a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the stock's share price in the near future. View News Stories for Insulet.

Insulet saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 4,710,000 shares, an increase of 13.8% from the August 30th total of 4,140,000 shares. Based on an average daily trading volume, of 903,900 shares, the short-interest ratio is presently 5.2 days. Currently, 7.9% of the company's shares are sold short. View Insulet's Current Options Chain.

Some companies that are related to Insulet include FRESENIUS SE &/S (FSNUY), ResMed (RMD), Teleflex (TFX), DexCom (DXCM), ABIOMED (ABMD), Novocure (NVCR), Hill-Rom (HRC), Haemonetics (HAE), Integra Lifesciences (IART), Penumbra (PEN), Globus Medical (GMED), Tandem Diabetes Care (TNDM), NuVasive (NUVA), ICU Medical (ICUI) and Cantel Medical (CMD).

Based on aggregate information from My MarketBeat watchlists, some companies that other Insulet investors own include DexCom (DXCM), Tandem Diabetes Care (TNDM), Alibaba Group (BABA), NVIDIA (NVDA), Netflix (NFLX), Splunk (SPLK), ServiceNow (NOW), Coupa Software (COUP), EXACT Sciences (EXAS) and salesforce.com (CRM).

Insulet's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Envestnet Asset Management Inc. (0.04%), CIBC Private Wealth Group LLC (0.02%), Gradient Investments LLC (0.02%), First Hawaiian Bank (0.01%), HMS Capital Management LLC (0.00%) and Meeder Asset Management Inc. (0.00%). Company insiders that own Insulet stock include Aiman Abdel-Malek, Bradley A Thomas, Charles Alpuche, David A Lemoine, David Colleran, James C Mullen, John A Fallon, Michael L Levitz, Michael P Spears, Sally Crawford and Shacey Petrovic. View Institutional Ownership Trends for Insulet.

PODD stock was sold by a variety of institutional investors in the last quarter, including CIBC Private Wealth Group LLC. Company insiders that have sold Insulet company stock in the last year include Aiman Abdel-Malek, Charles Alpuche, David A Lemoine, David Colleran, John A Fallon, Michael L Levitz, Michael P Spears, Sally Crawford and Shacey Petrovic. View Insider Buying and Selling for Insulet.

PODD stock was purchased by a variety of institutional investors in the last quarter, including First Hawaiian Bank, Envestnet Asset Management Inc., Meeder Asset Management Inc., Cerebellum GP LLC, Juncture Wealth Strategies LLC, Wedbush Securities Inc., Gradient Investments LLC and HMS Capital Management LLC. View Insider Buying and Selling for Insulet.

Shares of PODD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PODD stock can currently be purchased for approximately $157.12.

Insulet has a market capitalization of $9.47 billion and generates $563.82 million in revenue each year. The medical instruments supplier earns $3.29 million in net income (profit) each year or $0.05 on an earnings per share basis. Insulet employs 1,169 workers across the globe.View Additional Information About Insulet.

The official website for Insulet is http://www.insulet.com/.

Insulet's mailing address is 100 NAGOG PARK, ACTON MA, 01720. The medical instruments supplier can be reached via phone at 978-600-7000 or via email at [email protected]